Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNX NYSE:INS NASDAQ:USXF NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNXFirst Trust Mid Cap Core AlphaDEX Fund$124.91-0.1%$120.20$93.19▼$127.98$1.21B1.228,691 shs9,696 shsINSCoreCard$0.00$30.52▼$54.58$349.35MN/A49,198 shs17,000 shsUSXFiShares ESG Advanced MSCI USA ETF$56.45-0.9%$55.71$40.01▼$57.27$1.28B1.03119,253 shs2.28 million shsZYMEZymeworks$15.84-0.6%$13.97$9.03▼$17.70$1.19B1.27526,354 shs389,176 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNXFirst Trust Mid Cap Core AlphaDEX Fund-0.14%-0.20%+4.27%+11.68%+10.13%INSCoreCard0.00%0.00%0.00%0.00%0.00%USXFiShares ESG Advanced MSCI USA ETF-0.02%+1.32%+1.59%+10.74%+18.13%ZYMEZymeworks+1.21%+4.87%+10.93%+30.15%+27.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNXFirst Trust Mid Cap Core AlphaDEX Fund$124.91-0.1%$120.20$93.19▼$127.98$1.21B1.228,691 shs9,696 shsINSCoreCard$0.00$30.52▼$54.58$349.35MN/A49,198 shs17,000 shsUSXFiShares ESG Advanced MSCI USA ETF$56.45-0.9%$55.71$40.01▼$57.27$1.28B1.03119,253 shs2.28 million shsZYMEZymeworks$15.84-0.6%$13.97$9.03▼$17.70$1.19B1.27526,354 shs389,176 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNXFirst Trust Mid Cap Core AlphaDEX Fund-0.14%-0.20%+4.27%+11.68%+10.13%INSCoreCard0.00%0.00%0.00%0.00%0.00%USXFiShares ESG Advanced MSCI USA ETF-0.02%+1.32%+1.59%+10.74%+18.13%ZYMEZymeworks+1.21%+4.87%+10.93%+30.15%+27.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNXFirst Trust Mid Cap Core AlphaDEX Fund 2.54Moderate Buy$124.91N/AINSCoreCard 0.00N/AN/AN/AUSXFiShares ESG Advanced MSCI USA ETF 2.87Moderate Buy$56.45N/AZYMEZymeworks 2.90Moderate Buy$21.4335.28% UpsideCurrent Analyst Ratings BreakdownLatest INS, USXF, ZYME, and FNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$13.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNXFirst Trust Mid Cap Core AlphaDEX FundN/AN/AN/AN/AN/AN/AINSCoreCardN/AN/AN/AN/AN/AN/AUSXFiShares ESG Advanced MSCI USA ETFN/AN/AN/AN/AN/AN/AZYMEZymeworks$122.87M9.69N/AN/A$6.63 per share2.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNXFirst Trust Mid Cap Core AlphaDEX FundN/AN/A14.19∞N/AN/AN/AN/AN/AINSCoreCardN/AN/A0.00N/AN/AN/AN/AN/AN/AUSXFiShares ESG Advanced MSCI USA ETFN/AN/A28.41∞N/AN/AN/AN/AN/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest INS, USXF, ZYME, and FNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFNXFirst Trust Mid Cap Core AlphaDEX Fund$1.471.18%N/AN/AN/AINSCoreCardN/AN/AN/AN/AN/AUSXFiShares ESG Advanced MSCI USA ETF$0.530.94%N/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ALatest INS, USXF, ZYME, and FNX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/15/2025USXFiShares ESG Advanced MSCI USA ETFquarterly$0.12510.89%9/16/20259/16/20259/19/20256/25/2025FNXFirst Trust Mid Cap Core AlphaDEX FundQuarterly$0.26710.93%6/26/20256/26/20256/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNXFirst Trust Mid Cap Core AlphaDEX FundN/AN/AN/AINSCoreCardN/AN/AN/AUSXFiShares ESG Advanced MSCI USA ETFN/AN/AN/AZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNXFirst Trust Mid Cap Core AlphaDEX FundN/AINSCoreCardN/AUSXFiShares ESG Advanced MSCI USA ETFN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipFNXFirst Trust Mid Cap Core AlphaDEX FundN/AINSCoreCardN/AUSXFiShares ESG Advanced MSCI USA ETFN/AZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNXFirst Trust Mid Cap Core AlphaDEX Fund147,0009.70 millionN/ANot OptionableINSCoreCardN/A8.70 millionN/ANot OptionableUSXFiShares ESG Advanced MSCI USA ETF147,00022.70 millionN/AOptionableZYMEZymeworks46075.17 million67.56 millionOptionableINS, USXF, ZYME, and FNX HeadlinesRecent News About These CompaniesZymeworks Inc. $ZYME Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16 at 3:06 AM | marketbeat.comBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7, 2025 | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMedtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Archer's Flight Milestones & Defense Wins Excite Wall Street By Jeffrey Neal Johnson | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025INS, USXF, ZYME, and FNX Company DescriptionsFirst Trust Mid Cap Core AlphaDEX Fund NASDAQ:FNX$124.91 -0.07 (-0.06%) As of 03:46 PM EasternThe First Trust Mid Cap Core AlphaDEX Fund (FNX) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Mid Cap Core index. The fund tracks a tiered equal-weighted index of US mid-cap equities selected using both growth and value screens. FNX was launched on May 8, 2007 and is managed by First Trust.CoreCard NYSE:INSCoreCard Corp. engages in the management of emerging technology companies. It operates through CoreCard Software, Inc. and affiliate companies, which are involved in the design, development, and marketing of software solutions to corporations, financial institutions, retailers, and processors to manage credit and debit cards, prepaid cards, private label cards, fleet cards, loyalty programs, and accounts receivable and small loan transactions. The company was founded in 1973 and is headquartered in Norcross, GA.iShares ESG Advanced MSCI USA ETF NASDAQ:USXF$56.45 -0.49 (-0.86%) Closing price 04:00 PM EasternExtended Trading$56.46 +0.01 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The iShares ESG Advanced MSCI USA ETF (USXF) is an exchange-traded fund that is based on the MSCI USA Choice ESG Screened index. The fund tracks an index of large- and mid-cap US equities screened for positive environmental, social and governance rating while also screening for involvement in controversial activities. USXF was launched on Jun 16, 2020 and is managed by BlackRock.Zymeworks NYSE:ZYME$15.84 -0.09 (-0.56%) Closing price 04:00 PM EasternExtended Trading$15.81 -0.03 (-0.19%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
